Objective
to report the 1-year safety and efficacy of bivalirudin compared to unfractionated heparin given to patients with ACS scheduled for PCI
Study
open-label multicentre superiority two-nested randomised trial
Population
patients with ACS
Endpoints
MACE: all-cause death, MI or stroke (heparin vs. bivalirudin). NACE: all-cause death, MI, stroke or major bleeding
Conclusion
bivalirudin was not associated with lower MACE or NACE at 1 year compared to unfractionated heparin for ACS patients undergoing PCI
Valgimigli et al. Lancet. 2018;392:835-48
